Valuation: Theralase Technologies Inc.

Market Cap 76.87M 54.37M 47.56M 43.87M 40.51M 5.19B 78.17M 524M 206M 2.55B 204M 200M 8.78B P/E 2026 *
-26x
P/E 2027 * 13x
Enterprise Value 76.87M 54.37M 47.56M 43.87M 40.51M 5.19B 78.17M 524M 206M 2.55B 204M 200M 8.78B EV / Sales 2026 *
95.9x
EV / Sales 2027 * 2.27x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 day-5.45%
Current month+1.96%
1 month+10.64%
3 months-8.77%
6 months+6.12%
Current year+57.58%
1 week 0.26
Extreme 0.255
0.28
1 month 0.22
Extreme 0.225
0.28
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
05-21Buy

Director

20,900 0.0081%
05-20Sell

Chief Executive Officer

25,000 0.0097%
05-20Option

Chief Technology Officer

11,000 0.0043%
Change 5-day change 1-year change 3-year change Capi.($)
-5.45%0.00%+30.00%-11.86% 54.37M
-0.85%-6.52%+41.35%+46.81% 1.5B
+1.11%-3.11%-43.80%-50.62% 286M
+3.24%-0.45%-8.61%-49.32% 54.16M
Average -0.49%-2.52%+4.73%-16.25% 473.07M
Weighted average by Cap. -0.57%-5.64%+26.70%+27.62%

Financials

2026 *2027 *
Net sales 802K 567K 496K 458K 423K 54.1M 815K 5.47M 2.15M 26.65M 2.13M 2.08M 91.62M 33.89M 23.97M 20.96M 19.34M 17.86M 2.29B 34.46M 231M 90.73M 1.13B 89.99M 88.03M 3.87B
Net income -4.2M -2.97M -2.6M -2.4M -2.21M -283M -4.27M -28.63M -11.24M -140M -11.15M -10.91M -480M 6.83M 4.83M 4.23M 3.9M 3.6M 461M 6.95M 46.57M 18.29M 227M 18.14M 17.75M 780M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
10/07/26 CA$0.2600 -5.45% 140,775
09/07/26 CA$0.2750 +1.85% 141,737
08/07/26 CA$0.2700 -3.57% 37,220
07/07/26 CA$0.2800 +3.70% 81,700
06/07/26 CA$0.2700 +3.85% 65,744
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2600CAD
Average target price
0.7000CAD
Spread / Average Target
+169.23%

Quarterly revenue - Rate of surprise